FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128164908> ?p ?o ?g. }

• W3128164908 abstract "Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved cancer treatment but are known to cause cardiotoxicity. The pathophysiological consequences of TKI therapy are likely to manifest across different cell types of the heart, yet there is little understanding of the differential adverse cellular effects. Cardiac fibroblasts (CFs) play a pivotal role in the repair and remodeling of the heart following insult or injury, yet their involvement in anti-cancer drug induced cardiotoxicity has been largely overlooked. Here, we examine the direct effects of sunitinib malate and imatinib mesylate on adult rat CF viability, Ca 2+ handling and mitochondrial function that may contribute to TKI-induced cardiotoxicity. In particular, we investigate whether Ca 2+ /calmodulin dependent protein kinase II (CaMKII), may be a mediator of TKI-induced effects. Methods: CF viability in response to chronic treatment with both drugs was assessed using MTT assays and flow cytometry analysis. Calcium mobilization was assessed in CFs loaded with Fluo4-AM and CaMKII activation via oxidation was measured via quantitative immunoblotting. Effects of both drugs on mitochondrial function was determined by live mitochondrial imaging using MitoSOX red. Results: Treatment of CFs with sunitinib (0.1–10 μM) resulted in concentration-dependent alterations in CF phenotype, with progressively significant cell loss at higher concentrations. Flow cytometry analysis and MTT assays revealed increased cell apoptosis and necrosis with increasing concentrations of sunitinib. In contrast, equivalent concentrations of imatinib resulted in no significant change in cell viability. Both sunitinib and imatinib pre-treatment increased Angiotensin II-induced intracellular Ca 2+ mobilization, with only sunitinib resulting in a significant effect and also causing increased CaMKII activation via oxidation. Live cell mitochondrial imaging using MitoSOX red revealed that both sunitinib and imatinib increased mitochondrial superoxide production in a concentration-dependent manner. This effect in response to both drugs was suppressed in the presence of the CaMKII inhibitor KN-93. Conclusions: Sunitinib and imatinib showed differential effects on CFs, with sunitinib causing marked changes in cell viability at concentrations where imatinib had no effect. Sunitinib caused a significant increase in Angiotensin II-induced intracellular Ca 2+ mobilization and both TKIs caused increased mitochondrial superoxide production. Targeted CaMKII inhibition reversed the TKI-induced mitochondrial damage. These findings highlight a new role for CaMKII in TKI-induced cardiotoxicity, particularly at the level of the mitochondria, and confirm differential off-target toxicity in CFs, consistent with the differential selectivity of sunitinib and imatinib." @default.
• W3128164908 created "2021-02-15" @default.
• W3128164908 creator A5005927425 @default.
• W3128164908 creator A5030525094 @default.
• W3128164908 creator A5038606968 @default.
• W3128164908 creator A5056536934 @default.
• W3128164908 creator A5061986276 @default.
• W3128164908 date "2021-02-01" @default.
• W3128164908 modified "2023-10-01" @default.
• W3128164908 title "Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II" @default.
• W3128164908 cites W1918725443 @default.
• W3128164908 cites W1967676836 @default.
• W3128164908 cites W1969154199 @default.
• W3128164908 cites W1997143297 @default.
• W3128164908 cites W1998990808 @default.
• W3128164908 cites W2034998169 @default.
• W3128164908 cites W2040846930 @default.
• W3128164908 cites W2051363215 @default.
• W3128164908 cites W2067824561 @default.
• W3128164908 cites W2075775855 @default.
• W3128164908 cites W2081953717 @default.
• W3128164908 cites W2082301583 @default.
• W3128164908 cites W2087107619 @default.
• W3128164908 cites W2090004346 @default.
• W3128164908 cites W2091583229 @default.
• W3128164908 cites W2099540110 @default.
• W3128164908 cites W2100007538 @default.
• W3128164908 cites W2102708069 @default.
• W3128164908 cites W2104372934 @default.
• W3128164908 cites W2105025199 @default.
• W3128164908 cites W2114780053 @default.
• W3128164908 cites W2118103758 @default.
• W3128164908 cites W2119010176 @default.
• W3128164908 cites W2125304966 @default.
• W3128164908 cites W2131387907 @default.
• W3128164908 cites W2145064936 @default.
• W3128164908 cites W2157394282 @default.
• W3128164908 cites W2159453909 @default.
• W3128164908 cites W2159594706 @default.
• W3128164908 cites W2166641352 @default.
• W3128164908 cites W2167665047 @default.
• W3128164908 cites W2231291760 @default.
• W3128164908 cites W2279656465 @default.
• W3128164908 cites W2292667920 @default.
• W3128164908 cites W2406239697 @default.
• W3128164908 cites W2507771140 @default.
• W3128164908 cites W2766242430 @default.
• W3128164908 cites W2807811843 @default.
• W3128164908 cites W2883234257 @default.
• W3128164908 cites W2923054158 @default.
• W3128164908 cites W2973121798 @default.
• W3128164908 cites W3044534977 @default.
• W3128164908 cites W3083084296 @default.
• W3128164908 cites W4241520076 @default.
• W3128164908 doi "https://doi.org/10.3389/fcvm.2020.630480" @default.
• W3128164908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7882511" @default.
• W3128164908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33598481" @default.
• W3128164908 hasPublicationYear "2021" @default.
• W3128164908 type Work @default.
• W3128164908 sameAs 3128164908 @default.
• W3128164908 citedByCount "10" @default.
• W3128164908 countsByYear W31281649082021 @default.
• W3128164908 countsByYear W31281649082022 @default.
• W3128164908 countsByYear W31281649082023 @default.
• W3128164908 crossrefType "journal-article" @default.
• W3128164908 hasAuthorship W3128164908A5005927425 @default.
• W3128164908 hasAuthorship W3128164908A5030525094 @default.
• W3128164908 hasAuthorship W3128164908A5038606968 @default.
• W3128164908 hasAuthorship W3128164908A5056536934 @default.
• W3128164908 hasAuthorship W3128164908A5061986276 @default.
• W3128164908 hasBestOaLocation W31281649081 @default.
• W3128164908 hasConcept C121608353 @default.
• W3128164908 hasConcept C126322002 @default.
• W3128164908 hasConcept C170493617 @default.
• W3128164908 hasConcept C181080969 @default.
• W3128164908 hasConcept C185592680 @default.
• W3128164908 hasConcept C190283241 @default.
• W3128164908 hasConcept C2777583451 @default.
• W3128164908 hasConcept C2778233292 @default.
• W3128164908 hasConcept C2778729363 @default.
• W3128164908 hasConcept C2778820342 @default.
• W3128164908 hasConcept C2779490328 @default.
• W3128164908 hasConcept C29730261 @default.
• W3128164908 hasConcept C3019892230 @default.
• W3128164908 hasConcept C42362537 @default.
• W3128164908 hasConcept C502942594 @default.
• W3128164908 hasConcept C519063684 @default.
• W3128164908 hasConcept C53227056 @default.
• W3128164908 hasConcept C55493867 @default.
• W3128164908 hasConcept C71924100 @default.
• W3128164908 hasConcept C98274493 @default.
• W3128164908 hasConceptScore W3128164908C121608353 @default.
• W3128164908 hasConceptScore W3128164908C126322002 @default.
• W3128164908 hasConceptScore W3128164908C170493617 @default.
• W3128164908 hasConceptScore W3128164908C181080969 @default.
• W3128164908 hasConceptScore W3128164908C185592680 @default.
• W3128164908 hasConceptScore W3128164908C190283241 @default.
• W3128164908 hasConceptScore W3128164908C2777583451 @default.
• W3128164908 hasConceptScore W3128164908C2778233292 @default.
• W3128164908 hasConceptScore W3128164908C2778729363 @default.

• next